Although a pervious meta-analysis (Xie et al., 2018) showed that daprodustat could improve Hb without increasing adverse events in CKD patients, this study only included randomized controlled trials (RCTs) that compared with daprodustat and placebo but not daprodustat vs. rhEPO, and the evidence for efficacy and safety of daprodustat in two distinct groups of NDD patients and DD patients is lacking. Here, GSTM1 is linked to chronic kidney disease.